All In Biotech

Drug Trial Radar · NCT05178342

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)

Last checked: Nov 20, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

38

Actual

Start

Jan 1, 2022

Primary completion

Jul 31, 2024

Study completion Jul 31, 2024

Sponsor

Lead sponsor
University of LeipzigAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Curis, Inc.
First posted
Jan 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anemia in LR-MDS patients

Conditions

  • Myelodysplastic Syndromes
  • Anemia

Interventions

  • CA-4948Drug

    Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off. Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Erythroid response (HI-E)Time frame: At the end of cycle 4 (each cycle is 28 days).

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Charité Berlin - Campus Benjamin Franklin, Med. Klinik m. S. Hämatologie, Onkologie, Tumorimmunologie

    Berlin, Germany

  • Carl-Thiem-Klinikum Cottbus gGmbH, 2. Med. Klinik

    Cottbus, Germany

  • Gemeinschaftspraxis Dr. Jacobasch Dresden, Hämatologie Onkologie

    Dresden, Germany

  • Marienhospital Düsseldorf, Klinik für Onkologie und Hämatologie, Palliativmedizin

    Düsseldorf, Germany

  • ONCOSEARCH, Institut für Klinische Studien GbR

    Erlangen, Germany

  • InVO-Institut für Versorgungsforschung in der Onkologie

    Koblenz, Germany

  • VK & K Studien GbR, Studienzentrum

    Landshut, Germany

  • University Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, Hämostaseologie

    Leipzig, Germany

  • Universitätsklinikum Schleswig-Holstein, Klinik für Hämatologie und Onkologie Campus Lübeck

    Lübeck, Germany

  • Universitätsklinikum Mainz, III. Medizinische Klinik und Poliklinik - Hämatologie, Internistische Onkologie und Pneumologie

    Mainz, Germany

  • Universitätsklinikum Mannheim, III. Medizinische Klinik - Hämatologie und Onkologie

    Mannheim, Germany

  • Klinikum Hochsauerland GmbH, Klinik f. Hämatologie, Onkologie, Palliativmedizin, Stammzelltransplantation

    Meschede, Germany

  • Klinikum rechts der Isar der TU München III. Medizinische Klinik - Hämatologie und Onkologie

    München, Germany

  • Friedrich-Ebert-Krankenhaus GmbH, Klinik für Hämatologie, Onkologie und Nephrologie

    Neumünster, Germany

  • Rems-Murr-Kliniken gGmbH, Hämatologie, Onkologie und Palliativmedizin

    Winnenden, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.